


## Investigational Trials of Iberdomide (CC-220) in Patients With Relapsed or Refractory Lymphomas

## CC-220-NHL-001


A Phase 1/2, Multicenter, Open-Label Study to Assess Safety,
Pharmacokinetics, and Preliminary Efficacy of Iberdomide (CC-220),
Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb)
in Subjects With Relapsed or Refractory Lymphomas<sup>1,2</sup>



CONTACT: ClinicalTrialDisclosure@bms.com

## CC-220-DLBCL-002

A Phase 1b/2 Randomized, Multicenter, Open-Label Study of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy for Subjects With Relapsed or Refractory Aggressive B-Cell Lymphoma<sup>3</sup>



CONTACT: ClinicalTrialDisclosure@bms.com

## Enrollina soon4

A Phase 1B, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated, Poor Risk (IPI 3-5), Aggressive B-Cell Lymphoma

CONTACT: ClinicalTrialDisclosure@bms.com

The safety and efficacy of iberdomide (CC-220) and/or its uses are under investigation and have not been established.

There is no guarantee that iberdomide (CC-220) will receive health authority approval or become commercially available in any country for the uses being investigated.

\*Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma.

ABC, activated B-cell; AE, part and every event; All, adverse event; All, alanine aminotransferase; BCL, B-cell lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; DR, duration of response; EW, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; FL,

1. Clinicaltrials.gov. NCT04464798. Accessed October 29, 2020. 2. Bristol-Myers Squibb Company. Data on file (protocol number CC-220-NHL-001). 3. Bristol-Myers Squibb Company. Data on file (protocol number CC-220-NHC-001).